Recent health and medicine developments highlight new pharmaceutical approvals, clinical trial outcomes, and public health studies.

The UK Health Security Agency estimated that cold weather was linked to 2,200 deaths in England last winter, warning that even short cold spells can elevate mortality for weeks.

New phase 3 subgroup data indicate that obefazimod provides sustained clinical and endoscopic efficacy in patients with ulcerative colitis who experienced prior treatment failures.

The FDA approved the first generic once-weekly hormone therapy patch, designed to treat menopause symptoms and prevent osteoporosis in postmenopausal women.

A new UK trial named AD-SMART will test several repurposed drugs against a shared placebo group to evaluate potential treatments for Alzheimer disease more efficiently.

A nine-valent E coli vaccine successfully produced strong antibody responses in older adults with recent urinary tract infections, but ultimately failed to protect against invasive disease.

A recent meta-analysis suggests perioperative use of ketamine and esketamine may lower the incidence of postoperative delirium in adult surgical patients, though evidence remains inconclusive.

A comprehensive Cochrane review found that physician exposure to pharmaceutical industry marketing, including gifts and sales visits, is associated with lower-quality prescribing habits.

Adding sotatercept to treatment regimens for children with pulmonary hypertension may improve their daily activity levels and enhance key measures of heart and lung health.